AMGN Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
AMGN is not a good buy right now for a beginner long-term investor with $50,000-$100,000 who wants a clear, immediate entry. The stock is technically strong, but it is already overbought and trading near resistance, while analyst sentiment is mixed and recent news introduces a meaningful negative catalyst. I would not buy aggressively at current levels; the better call is hold and wait for a cleaner setup.
AMGN's trend is bullish in the short to medium term: MACD histogram is positive and expanding, and the moving averages are aligned bullishly (SMA_5 > SMA_20 > SMA_200). However, RSI_6 at 85.1 is deeply overbought, which suggests the stock may be extended after the recent move. Price at 373.76 is sitting near resistance at R1 370.44 and below R2 380.14, so upside from here looks limited in the very short term. The technical picture is strong, but the current entry is not attractive for an impatient buyer.
Recent analyst commentary includes several constructive views: Piper Sandler kept Overweight and sees continued top-line upside from rare disease assets like Uplizna and potential strength from Tepezza; Freedom Broker upgraded AMGN to Buy; Morgan Stanley raised its price target after an in-line quarter; and Truist noted modest FY26 guidance improvement. News also mentioned Amgen reporting significant revenue growth, which supports the growth narrative. Congress trading was balanced but included three purchase transactions, which is a mild positive signal.
The recent technical overbought condition is another near-term headwind.
Latest quarter: Q1 2026. The company reported inline revenue, beat on EPS, and raised guidance modestly. The earnings beat was helped by lower SG&A and taxes, while analysts described the quarter as seasonally weak but still supportive of the innovative portfolio. Overall, the latest quarter shows stable growth momentum rather than breakout acceleration.
Analyst sentiment is mixed to mildly positive. Recent price targets were revised mostly downward or only modestly upward, with Mizuho cutting target to $303 and keeping Neutral, Goldman Sachs cutting target to $389 but keeping Buy, Piper Sandler maintaining Overweight with constructive growth commentary, Freedom Broker upgrading to Buy, and several firms staying Hold/Equal Weight. Wall Street's pros see continued growth from the innovative and rare disease portfolio, while the cons view focuses on slower sales growth, limited medium-term upside, and regulatory risk around Tavneos.
